AKT1 and Ewing sarcoma: Given that chemotherapy induces Akt/ERK activation (Fig. 1b–d), which could be suppressed by TAM kinases inhibitions via UNC2025 or UNC5293 (Fig. 2c), and genetic depletion of either MERTK or TYRO3 sensitized Ewing sarcoma cells to SN-38 or etoposide (Fig. 2g–k), we examined whether UNC2025 or UNC5293 synergizes with chemotherapy to reduce Ewing sarcoma growth.